WallStreetZenWallStreetZen

NASDAQ: ENTA
Enanta Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ENTA past revenue growth

How has ENTA's revenue growth performed historically?
Company
-10.32%
Industry
144.63%
Market
17.55%
ENTA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ENTA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ENTA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ENTA earnings and revenue history

Current Revenue
$73.6M
Current Earnings
-$138.2M
Current Profit Margin
-187.8%

ENTA Return on Equity

Current Company
-60.4%
Current Industry
-63.5%
Current Market
188%
ENTA's Return on Equity (-60.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ENTA announces earnings.

ENTA Return on Assets

Current Company
-32.3%
Current Industry
2.9%
ENTA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ENTA Return on Capital Employed

Current Company
-34.8%
Current Industry
19.5%
ENTA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ENTA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ENTA$73.62M-$124.91M-$138.24M-20.94%N/A
CDXC$83.57M-$3.23M-$4.94M+21.50%N/A
VNDA$192.64M$9.35M$2.51M-0.05%-39.66%
ADAP$60.28M-$102.70M-$113.87M+0.26%N/A
IVVD$0.00-$196.62M-$198.64MN/AN/A
View Top Biotech Stocks

ENTA earnings dates

Next earnings date
May 6, 2024

Enanta Pharmaceuticals Earnings & Revenue FAQ

What were ENTA's earnings last quarter?

On Invalid Date, Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q4 2023 earnings per share (EPS) of -$1.58, up 13.67% year over year. Total Enanta Pharmaceuticals earnings for the quarter were -$33.41 million. In the same quarter last year, Enanta Pharmaceuticals's earnings per share (EPS) was -$1.39.

If you're new to stock investing, here's how to buy Enanta Pharmaceuticals stock.

What was ENTA's earnings growth in the past year?

As of Q2 2024, Enanta Pharmaceuticals's earnings has grown year over year. Enanta Pharmaceuticals's earnings in the past year totalled -$138.24 million.

What is ENTA's earnings date?

Enanta Pharmaceuticals's earnings date is Invalid Date. Add ENTA to your watchlist to be reminded of ENTA's next earnings announcement.

What was ENTA's revenue last quarter?

On Invalid Date, Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q4 2023 revenue of $18.00 million up 23.67% year over year. In the same quarter last year, Enanta Pharmaceuticals's revenue was $23.59 million.

What was ENTA's revenue growth in the past year?

As of Q2 2024, Enanta Pharmaceuticals's revenue has grown -10.32% year over year. This is 154.95 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Enanta Pharmaceuticals's revenue in the past year totalled $73.62 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.